The American health system is poised to incur $55 billion in excess costs from pharmaceutical companies’ strategies to delay competition on three drugs
The American health system is poised to incur $55 billion in excess costs from pharmaceutical companies’ strategies to delay competition on three drugs
Partner with us now to build
a more just and equitable
medicine system for all.